Elaine Coustan-Smith1, Guangchun Song2, Sheila Shurtleff2, Allen Eng-Juh Yeoh1,3, Wee Joo Chng3, Siew Peng Chen1, Jeffrey E Rubnitz4,5, Ching-Hon Pui2,4,5, James R Downing2,5, Dario Campana1,3. 1. Department of Pediatrics, National University of Singapore, Singapore. 2. Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. 3. National University Cancer Institute, Singapore, National University of Singapore, Singapore. 4. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. 5. University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Abstract
BACKGROUND: Optimal management of acute myeloid leukemia (AML) requires monitoring of treatment response, but minimal residual disease (MRD) may escape detection. We sought to identify distinctive features of AML cells for universal MRD monitoring. METHODS: We compared genome-wide gene expression of AML cells from 157 patients with that of normal myeloblasts. Markers encoded by aberrantly expressed genes, including some previously associated with leukemia stem cells, were studied by flow cytometry in 240 patients with AML and in nonleukemic myeloblasts from 63 bone marrow samples. RESULTS: Twenty-two (CD9, CD18, CD25, CD32, CD44, CD47, CD52, CD54, CD59, CD64, CD68, CD86, CD93, CD96, CD97, CD99, CD123, CD200, CD300a/c, CD366, CD371, and CX3CR1) markers were aberrantly expressed in AML. Leukemia-associated profiles defined by these markers extended to immature CD34+CD38- AML cells; expression remained stable during treatment. The markers yielded MRD measurements matching those of standard methods in 208 samples from 52 patients undergoing chemotherapy and revealed otherwise undetectable MRD. They allowed MRD monitoring in 129 consecutive patients, yielding prognostically significant results. Using a machine-learning algorithm to reduce high-dimensional data sets to 2-dimensional data, the markers allowed a clear visualization of MRD and could detect 1 leukemic cell among more than 100,000 normal cells. CONCLUSION: The markers uncovered in this study allow universal and sensitive monitoring of MRD in AML. In combination with contemporary analytical tools, the markers improve the discrimination between leukemic and normal cells, thus facilitating data interpretation and, hence, the reliability of MRD results. FUNDING: National Cancer Institute (CA60419 and CA21765); American Lebanese Syrian Associated Charities; National Medical Research Council of Singapore (1299/2011); Viva Foundation for Children with Cancer, Children's Cancer Foundation, Tote Board & Turf Club, and Lee Foundation of Singapore.
BACKGROUND: Optimal management of acute myeloid leukemia (AML) requires monitoring of treatment response, but minimal residual disease (MRD) may escape detection. We sought to identify distinctive features of AML cells for universal MRD monitoring. METHODS: We compared genome-wide gene expression of AML cells from 157 patients with that of normal myeloblasts. Markers encoded by aberrantly expressed genes, including some previously associated with leukemia stem cells, were studied by flow cytometry in 240 patients with AML and in nonleukemic myeloblasts from 63 bone marrow samples. RESULTS: Twenty-two (CD9, CD18, CD25, CD32, CD44, CD47, CD52, CD54, CD59, CD64, CD68, CD86, CD93, CD96, CD97, CD99, CD123, CD200, CD300a/c, CD366, CD371, and CX3CR1) markers were aberrantly expressed in AML. Leukemia-associated profiles defined by these markers extended to immature CD34+CD38- AML cells; expression remained stable during treatment. The markers yielded MRD measurements matching those of standard methods in 208 samples from 52 patients undergoing chemotherapy and revealed otherwise undetectable MRD. They allowed MRD monitoring in 129 consecutive patients, yielding prognostically significant results. Using a machine-learning algorithm to reduce high-dimensional data sets to 2-dimensional data, the markers allowed a clear visualization of MRD and could detect 1 leukemic cell among more than 100,000 normal cells. CONCLUSION: The markers uncovered in this study allow universal and sensitive monitoring of MRD in AML. In combination with contemporary analytical tools, the markers improve the discrimination between leukemic and normal cells, thus facilitating data interpretation and, hence, the reliability of MRD results. FUNDING: National Cancer Institute (CA60419 and CA21765); American Lebanese Syrian Associated Charities; National Medical Research Council of Singapore (1299/2011); Viva Foundation for Children with Cancer, Children's Cancer Foundation, Tote Board & Turf Club, and Lee Foundation of Singapore.
Authors: Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana Journal: Lancet Oncol Date: 2010-05-05 Impact factor: 41.316
Authors: A Venditti; F Buccisano; G Del Poeta; L Maurillo; A Tamburini; C Cox; A Battaglia; G Catalano; B Del Moro; L Cudillo; M Postorino; M Masi; S Amadori Journal: Blood Date: 2000-12-01 Impact factor: 22.113
Authors: Francesco Buccisano; Luca Maurillo; Maria Ilaria Del Principe; Giovanni Del Poeta; Giuseppe Sconocchia; Francesco Lo-Coco; William Arcese; Sergio Amadori; Adriano Venditti Journal: Blood Date: 2011-10-28 Impact factor: 22.113
Authors: Anne S Roug; Hanne Ø Larsen; Line Nederby; Tom Just; Gordon Brown; Charlotte G Nyvold; Hans B Ommen; Peter Hokland Journal: Br J Haematol Date: 2013-10-24 Impact factor: 6.998
Authors: Elisabet Björklund; Astrid Gruber; Joanna Mazur; Anna Mårtensson; Mona Hansson; Anna Porwit Journal: Int J Hematol Date: 2009-08-29 Impact factor: 2.490
Authors: A Macedo; A Orfão; M B Vidriales; M C López-Berges; B Valverde; M González; M D Caballero; F Ramos; M Martínez; J Fernández-Calvo Journal: Ann Hematol Date: 1995-04 Impact factor: 3.673
Authors: Johannes Schmoellerl; Inês Amorim Monteiro Barbosa; Thomas Eder; Tania Brandstoetter; Luisa Schmidt; Barbara Maurer; Selina Troester; Ha Thi Thanh Pham; Mohanty Sagarajit; Jessica Ebner; Gabriele Manhart; Ezgi Aslan; Stefan Terlecki-Zaniewicz; Christa Van der Veen; Gregor Hoermann; Nicolas Duployez; Arnaud Petit; Helene Lapillonne; Alexandre Puissant; Raphael Itzykson; Richard Moriggl; Michael Heuser; Roland Meisel; Peter Valent; Veronika Sexl; Johannes Zuber; Florian Grebien Journal: Blood Date: 2020-07-23 Impact factor: 22.113
Authors: Lucas Touzet; Florent Dumezy; Christophe Roumier; Céline Berthon; Claire Bories; Bruno Quesnel; Claude Preudhomme; Thomas Boyer Journal: Cancer Med Date: 2019-02-10 Impact factor: 4.452